## UTHR: United Therapeutics Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.44 indicates fundamental undervaluation. Quality metrics strong (ROE 20%, ROA 13%). Caution: momentum weakening (-2.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($453.32)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Rothblatt, United Therapeutics CEO, sells $3.8m in UTHR stock By Investing.com**
- Source: Investing.com India | 20251208T220901 | Neutral | Relevance: 99%
-  Martine Rothblatt, CEO of United Therapeutics Corp (NASDAQ:UTHR), sold 8,000 shares of company stock for approximately $3.87 million between December 5 and December 8, 2025. These sales were part of a pre-arranged 10b5-1 trading plan, even as Rothblatt simultaneously exercised stock options to acquire an equal number of shares. The company maintains strong financial health, and analysts have a positive outlook, despite a recent revenue shortfall.

**2. Amundi Has $107.11 Million Position in United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251208T080938 | Somewhat-Bullish | Relevance: 99%
-  Amundi significantly increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, now holding 362,826 shares valued at approximately $107.11 million. Despite a recent earnings beat on EPS but a revenue miss, the company holds a "Moderate Buy" consensus rating from analysts, with a target price of $505.00. Insider selling has been notable, with officers selling off a substantial amount of shares in the past 90 days, even as institutional investors own the vast majority of the stock.

**3. United Therapeutics Corporation $UTHR Shares Sold by L2 Asset Management LLC**
- Source: MarketBeat | 20251208T120938 | Neutral | Relevance: 98%
-  L2 Asset Management LLC significantly reduced its stake in United Therapeutics Corporation (UTHR), selling 35.6% of its shares. This comes amidst broader insider selling activity, with executives selling a substantial number of shares in recent months. Despite this, United Therapeutics shows strong financial performance, trades near its 52-week high, and has a "Moderate Buy" consensus rating from analysts who have set an average price target of $505.

**4. United Therapeutics Corporation $UTHR Shares Bought by First Trust Advisors LP**
- Source: MarketBeat | 20251207T110325 | Somewhat-Bullish | Relevance: 98%
-  First Trust Advisors LP increased its stake in United Therapeutics Corporation by 2.5% in Q2, bringing their total to 305,512 shares. Institutional investors collectively own 94.08% of the company, with significant additions from Vanguard and Invesco. Despite insider sales totaling over $264 million in the last quarter, analysts maintain a "Moderate Buy" rating with a $505 price target, as the stock trades near its 52-week high following an EPS beat.

**5. United Therapeutics Corporation $UTHR Shares Acquired by Marshall Wace LLP**
- Source: MarketBeat | 20251207T050325 | Somewhat-Bullish | Relevance: 96%
-  Marshall Wace LLP significantly increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 29.8% in Q2, now owning 276,480 shares valued at approximately $79.45 million. Despite recent insider selling, institutional ownership remains high, and analysts maintain a "Moderate Buy" rating with an average price target of $505.00. The biotechnology company reported strong Q3 earnings, surpassing consensus estimates, and continues to develop products addressing chronic and life-threatening diseases.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 15 ($11.95M) |
| Sells | 71 ($40.48M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Blackrock Inc.: 12.4% (+0.4%)
- Vanguard Group Inc: 10.3% (-0.7%)
- Renaissance Technolo: 5.1% (+2.6%)
- Avoro Capital Adviso: 4.7% (-14.7%)
- State Street Corpora: 4.5% (-11.3%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $40M sold (71 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.44 suggests fair value with growth premium. Forward P/E 16.7x stretched relative to 5% growth. Quality metrics strong (ROA 13%, margin 41%). Balance sheet: strong liquidity (6.4x), low leverage (D/E 0.12). Insider selling cluster ($40.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.5B |
| Beta | 0.86 |
| 52W Range | $266.98 - $492.62 |
| Short Interest | 5.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.44 |
| Forward P/E | 16.7 |
| Current P/E | 17.6 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.4% to -2.1% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.1pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.36x) but short-term weakness (below SMA20). MACD histogram bearish (-1.68), momentum weakening. RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.14% (CS: 43) | Weak |
| RSI_14 | 55.9 | Neutral |
| MACD Histogram | -1.68 | Bearish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 1.050x | Above |
| vs SMA200 | 1.357x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $476.36
- **Stop Loss:** $453.32 (4.8% risk)
- **Target:** $522.44 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 13
- **Position Value:** $6,192.68
- **Portfolio %:** 6.19%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-25 (Est: $6.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.96 | $7.16 | +2.9% |
| 2025Q2 | $6.94 | $6.41 | -7.6% |
| 2025Q1 | $6.28 | $6.63 | +5.6% |
| 2024Q4 | $6.27 | $6.19 | -1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*